{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:56:27Z","timestamp":1781664987150,"version":"3.54.5"},"reference-count":35,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background\/Objectives: The Systemic Immune\u2013Inflammation Index (SII), derived from routine blood counts, has emerged as a potential marker of systemic inflammation in psoriasis. However, its longitudinal behavior across different systemic and biologic therapies remains poorly characterized. This study aimed to evaluate changes in SII over time, assess its relationship with Psoriasis Area and Severity Index (PASI) scores, and compare SII trajectories among different treatment classes. Methods: A retrospective single-center study included 210 adults with psoriasis treated for 12 months with cyclosporine, anti-TNF-\u03b1, anti-IL-17, or anti-IL-23 agents. SII and PASI were recorded at baseline, 16, 36, and 52 weeks. Correlations between SII and PASI were assessed using Spearman\u2019s analysis. Longitudinal changes were evaluated using the Friedman test, and treatment-group differences were assessed using Kruskal\u2013Wallis analysis. An adjusted multivariable linear regression model including age, sex, body mass index, psoriatic arthritis, baseline PASI, and treatment group was performed to identify factors associated with \u0394%SII. Results: SII correlated with PASI at baseline (\u03c1 = 0.406, p &lt; 0.001) and at 52 weeks (\u03c1 = 0.186, p = 0.007), whereas no significant associations were observed at intermediate timepoints. Longitudinal analyses demonstrated significant differences in SII trajectories among treatment groups (p &lt; 0.001). SII increased over time in the cyclosporine and anti-TNF-\u03b1 groups, while anti-IL-17 and anti-IL-23 therapies were associated with marked and sustained reductions. In the adjusted model, anti-IL-17 (\u03b2 = \u221290.7, 95% CI \u2212119.6 to \u221261.8, p &lt; 0.001) and anti-IL-23 therapies (\u03b2 = \u221297.9, 95% CI \u2212126.2 to \u221269.6, p &lt; 0.001) remained independently associated with greater reductions in SII compared with cyclosporine, whereas anti-TNF therapy showed no significant difference. Conclusions: SII is a dynamic marker of systemic inflammatory changes in psoriasis and exhibits distinct longitudinal patterns according to treatment class. The pronounced reductions observed with IL-17 and IL-23 inhibitors support the potential value of SII as an adjunctive measure of systemic inflammation. However, prospective studies are required to clarify its clinical utility and determine its role in routine patient management.<\/jats:p>","DOI":"10.3390\/jpm16060323","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:58:38Z","timestamp":1781661518000},"page":"323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Immune\u2013Inflammation Index (SII) as a Predictive Biomarker of Therapeutic Response in Psoriasis: A Retrospective Comparative Analysis of Anti-TNF, Anti-IL-17, and Anti-IL-23 Agents"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-9206","authenticated-orcid":false,"given":"Emanuele","family":"Trovato","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"La Marca","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Simonini","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9441-3923","authenticated-orcid":false,"given":"Martina","family":"Dragotto","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Calandra","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lussana","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cartocci","sequence":"additional","affiliation":[{"name":"Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Rubegni","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: State of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Azuaga, A.B., Ram\u00edrez, J., and Ca\u00f1ete, J.D. (2023). Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054901"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","article-title":"The concept of psoriasis as a systemic inflammation: Implications for disease management","volume":"26","author":"Reich","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jdv.13891","article-title":"The prevalence of anxiety in patients with psoriasis: A systematic review of observational studies and clinical trials","volume":"31","author":"Fleming","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u2018psoriatic march\u2019: A concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.3390\/ijms26083868","article-title":"The Relationship Between Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index Markers and Response to Biological Therapy in Patients with Psoriasis","volume":"26","author":"Robak","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"ref_13","first-page":"291","article-title":"Systemic Immune-Inflammation Index as a Biomarker of Psoriasis Severity","volume":"5","author":"Pala","year":"2023","journal-title":"Arch. Basic Clin. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhao, X., Li, J., and Li, X. (2024). Association between systemic immune-inflammation index and psoriasis: A population-based study. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1305701"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Albanesi, C., Madonna, S., Gisondi, P., and Girolomoni, G. (2018). The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01549"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Nestle","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ad.2015.10.005","article-title":"Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/09546634.2015.1034072","article-title":"Systemic cyclosporine treatment in severe childhood psoriasis: A retrospective chart review","volume":"28","author":"Dogra","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0190-9622(88)70163-2","article-title":"Systemic retinoid therapy for psoriasis","volume":"19","author":"Lowe","year":"1988","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bucalo, A., Rega, F., Zangrilli, A., Silvestri, V., Valentini, V., Scafetta, G., Marraffa, F., Grassi, S., Rogante, E., and Piccolo, A. (2020). Paradoxical Psoriasis Induced by Anti-TNF\u03b1 Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217873"},{"key":"ref_21","first-page":"157","article-title":"Updated review of IL-17 inhibitors for psoriasis treatment","volume":"1","author":"Lian","year":"2018","journal-title":"Int. J. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s13555-025-01494-z","article-title":"Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)","volume":"15","author":"Pinter","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"ii104","DOI":"10.1136\/annrheumdis-2012-203037","article-title":"Biomarkers in psoriasis and psoriatic arthritis","volume":"72","author":"Villanova","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","first-page":"238","article-title":"Severe psoriasis\u2013oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, Z., Zhang, J., Luo, S., and Zhao, X. (2021). Prognostic Significance of Systemic Immune-Inflammation Index in Patients with Diffuse Large B-Cell Lymphoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.655259"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41423-025-01380-w","article-title":"Neutrophils as critical orchestrators of chronic inflammation","volume":"23","author":"Torfs","year":"2026","journal-title":"Cell. Mol. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Riaz, B., and Sohn, S. (2023). Neutrophils in Inflammatory Diseases: Unraveling the Impact of Their Derived Molecules and Heterogeneity. Cells, 12.","DOI":"10.3390\/cells12222621"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e70050","DOI":"10.1002\/iid3.70050","article-title":"Association Between Systemic Immune-Inflammation Index and Psoriasis, Psoriasis Comorbidities, and All-Cause Mortality: A Study Based on NHANES","volume":"12","author":"Zhao","year":"2024","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wu, Y., Huang, Y., Wu, Y., Sun, J., Xie, Q., and Yin, G. (2025). Systemic immune-inflammation index as a versatile biomarker in autoimmune disorders: Insights from rheumatoid arthritis, lupus, and spondyloarthritis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1621209"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.5826\/dpc.1504a5733","article-title":"Therapeutic Modulation of Peripheral Blood Cells and Inflammatory Indices During 52 Weeks of Risankizumab in Responder Patients with Moderate-to-Severe Psoriasis","volume":"15","author":"Rosi","year":"2025","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.5826\/dpc.1601a5943","article-title":"Effectiveness of Biological Therapy in Psoriasis: Real-World Evaluation of SII and SIRI as Biomarkers of Systemic Inflammation","volume":"16","author":"Bardazzi","year":"2026","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ma, R., Cui, L., Cai, J., Yang, N., Wang, Y., Chen, Q., Chen, W., Peng, C., Qin, H., and Ding, Y. (2024). Association between systemic immune inflammation index, systemic inflammation response index and adult psoriasis: Evidence from NHANES. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1323174"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e71966","DOI":"10.1002\/hsr2.71966","article-title":"Association Between Inflammatory Cytokines and Systemic Inflammation Indices in Patients with Psoriasis: A Cross-Sectional Study","volume":"9","year":"2026","journal-title":"Health Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s11845-025-03969-6","article-title":"The effect of IL-17 and IL-23 \u0131nhibitors on hematological inflammatory parameters in patients with psoriasis vulgaris","volume":"194","year":"2025","journal-title":"Ir. J. Med. Sci."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/6\/323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:28:45Z","timestamp":1781663325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/6\/323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jpm16060323"],"URL":"https:\/\/doi.org\/10.3390\/jpm16060323","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}